63% Surge vs. 51% Drawdown: 8 Cross-Sector Picks Across Pharma, Tech, Consumer & Energy Shine on Mon

Hello everyone — a new week begins.

This week, TigerPicks highlights 8 stocks across healthcare, energy, technology and consumer sectors. The list ranges from a biotech name that surged more than 63% in one session, to an energy company signing a 20-year $Exxon Mobil(XOM)$ agreement, and software names still trading far below their recent highs.

Here’s what matters most.

🎁 Tiger Coins ahead: pick your favorite stock from this week’s 8 names and share your reason at the end for a chance to earn Tiger Coins.

💊 Pharma: Weight-Loss Drugs, M&A and a 63% Biotech Surge

$Eli Lilly(LLY)$

$1,227.11

+3.70%

Market cap ~$1.09T | 52-week range $685.15 - $1,249.45 | 1.8% from ATH

Lilly continues to trade close to record territory after another strong earnings report. Q2 revenue reached $22.97B, +48% YoY, comfortably ahead of the roughly $20.8B consensus, while non-GAAP EPS of $8.38 beat expectations of around $6.40.

The key engines remain Mounjaro and Zepbound, while investors are also watching Lilly’s oral obesity pipeline and next-generation candidate retatrutide.

What matters now: Lilly’s valuation is expensive, but its growth rate remains unusually strong. Consensus target is around $1,292, implying roughly 5% upside. The main risk is pricing: global net realised prices declined 13% YoY.

$AbbVie(ABBV)$

$258.82

+3.48%

Q2 revenue $16.99B | +10.2% YoY | Consensus target $276.42

AbbVie’s quarter showed that its post-Humira transition is gaining traction. Revenue rose 10.2%, while adjusted EPS increased 22.9% to $3.65.

The company is also moving ahead with its roughly $10.9B acquisition of Apogee Therapeutics, funded partly through a multi-billion-dollar debt offering.

The contrast inside the portfolio remains clear:

• Skyrizi: strong prescription momentum

• Humira: global revenue -35.9%

• Imbruvica: revenue -29%

Full-year adjusted EPS guidance was trimmed slightly to $13.87–$14.07, reflecting acquisition-related dilution.

What matters now: Skyrizi and Rinvoq increasingly need to replace Humira as AbbVie’s main growth engines. Short-term dilution from Apogee looks manageable, but the real value will depend on what the acquisition adds to the pipeline.

$Johnson & Johnson(JNJ)$

$271.05

+3.31%

Q2 revenue $25.31B | +6.6% YoY | Dividend yield ~2.0%

JNJ delivered another steady quarter. Revenue grew 6.6%, while adjusted EPS of $2.90 beat the $2.84 estimate.

Management also raised full-year guidance:

• Revenue: $100.8B–$101.4B

• Adjusted EPS: $11.60–$11.75

Growth was supported by Darzalex and Tremfya, while JNJ also continued building out its medtech portfolio through the AI-powered MONARCH QUEST 3 bronchoscopy system and progress on the OTTAVA robotic surgery platform.

The quarterly dividend stands at $1.34 per share.

What matters now: JNJ remains the defensive name in this group — steady earnings, dividend support and less dependence on a single growth theme. The stock is already around consensus fair value, so upside increasingly depends on execution rather than rerating.

$Amylyx Pharmaceuticals(AMLX)$

$35.11

+63.84%

52-week range $7.63 - $35.39 | New 52-week high | Institutional ownership 95.84%

Amylyx was easily the week’s most explosive mover, surging 63.84% on Aug. 18 and finishing near a fresh 52-week high.

From its $7.63 low, the stock has gained more than 360%.

The immediate catalyst was a wave of bullish analyst revisions:

• Mizuho: $24 → $30

• LifeSci Capital: Buy, $44

• Guggenheim: $30 → $40

• H.C. Wainwright: $55 target

The fundamentals remain much less dramatic. Q2 produced a $43.4M net loss, or $0.39 per share, while cash and short-term investments stood at $250.8M.

What matters now: this rally was driven primarily by analyst optimism rather than a sudden earnings breakthrough. With institutional ownership above 95%, the stock can move violently in either direction. This remains a high-risk biotech trade.

⚡ Energy: Long-Term Contracts Meet Permian Growth

$Targa Resources(TRGP)$

$298.40

+7.36%

Market cap $64.0B | 52-week range $144.14 - $305.08 | 2.2% from ATH

Targa was one of the week’s strongest large-cap performers after announcing a 20-year fee-based midstream agreement with ExxonMobil covering acreage in both the Delaware and Midland basins.

The agreement includes:

• long-term NGL dedications

• three new Delaware Basin gas-processing plants

• expanded NGL logistics

• the Bull Run II pipeline

Management also lifted FY26 growth capex from $4.5B to around $5B, while adjusted EBITDA guidance moved toward the top end of the $5.7B–$5.9B range.

Q2 EPS of $3.54 also beat the $2.83 estimate by a wide margin.

What matters now: the 20-year contract gives Targa unusually strong cash-flow visibility. The stock is already close to consensus fair value, so chasing after the latest move carries more risk, but the medium-term growth story remains intact.

💻 Tech & Consumer: Can the Beaten-Down Names Turn the Corner?

$Adobe(ADBE)$

$263.14

+3.58%

Market cap $101.0B | 52-week range $190.12 - $370.86 | -29% from 52-week high

Adobe bounced 3.58%, but the stock remains nearly 30% below its 52-week high.

Q2 fundamentals were still solid:

• Revenue: $6.62B, +12.7% YoY

• EPS: $5.96 vs. $5.82 expected

• Forward P/E: ~10x based on FY27 EPS estimates

The debate is valuation versus disruption.

Morgan Stanley turned more cautious and cut its price target to $240, citing AI competition, while CLSA initiated coverage at Outperform with a $300 target.

What matters now: Adobe looks inexpensive relative to its historical valuation, but investors want proof that Firefly and other AI products can strengthen rather than cannibalise the core Creative Cloud business. The next earnings report will be the key test.

$ulta beauty(ULTA)$

$516.74

+4.75%

Market cap $22.2B | 52-week range $443.60 - $714.97 | -27.7% from 52-week high

Ulta is attempting to stabilise after a substantial pullback. Shares gained 4.75%, with after-hours trading pushing them above $526.

Its latest quarter was better than expected:

• Q1 EPS: $7.74 vs. $6.89 expected

• Revenue: $3.16B

• FY EPS guidance: $28.36–$28.80

• FY revenue guidance: $13.1B–$13.3B

Twenty of 27 analysts rate the stock Buy or Strong Buy, with a consensus target around $638, implying roughly 23% upside.

What matters now: Q2 earnings on Aug. 27 are the immediate catalyst. Ulta still has strong loyalty and omnichannel advantages, but beauty spending remains tied to consumer confidence. Another earnings beat would strengthen the recovery case.

$Intuit(INTU)$

$350.41

+4.41%

Market cap $94.8B | 52-week range $252.84 - $721.54 | -51.4% from 52-week high

Intuit has suffered the deepest drawdown of this week’s picks, falling more than 51% from its 52-week high before rebounding 4.41%.

The underlying business remains profitable:

• Q3 FY26 revenue: $8.56B, +10.4% YoY

• EPS: $12.80 vs. $12.57 expected

• FY EPS guidance: $23.80–$23.85

• Forward P/E: ~16.5x

Analysts currently expect Q4 revenue of around $4.28B and EPS of roughly $3.54.

The main overhang is AI disruption. A securities class-action lawsuit has also alleged potentially misleading statements related to TurboTax growth and generative-AI competition.

What matters now: after such a large valuation reset, Intuit does not need explosive growth to rerate — but it does need to prove that AI strengthens TurboTax and QuickBooks rather than undermining them. The next earnings report is therefore critical.

One-Line Summary

All 8 stocks rose this week. Pharma led on earnings catalysts; tech and consumer names are showing rebound signs after deep pullbacks.

Next week: watch $Intuit(INTU)$ (Aug 25), $ulta beauty(ULTA)$ (Aug 27) earnings, and $Adobe(ADBE)$ (Sep 10) Q3 results. For ADBE and INTU, if earnings validate the AI transformation thesis, current valuations may offer an attractive risk-reward.

🐯 Tiger Coins Interaction

Which stock would you pick for the next 30 days?
LLY / ABBV / JNJ / AMLX / TRGP / ADBE / ULTA / INTU

And which setup do you prefer?

🔥 Momentum or 📉 Comeback

💰 Share your pick + reason in the comments for a chance to earn Tiger Coins!

Good allocation isn’t just about investing — it’s also about keeping everyday life organised.

Just like a well-balanced portfolio, the right organisation can make business trips, travel and workouts a little easier. The new Tiger Toiletry Bag features a dual-layer dry & wet separation design with plenty of space to keep your essentials neatly organised, wherever you go.

Redeem the new Tiger Toiletry Bag now in Tiger Coin Mall. https://laohu8.com/J/redeemGift?goodID=100538&type=delivery